Kenvue Inc., the manufacturer of Tylenol, faces a significant crisis ignited by former President Donald Trump's public warning against its most recognized product, coupled with impending regulatory action. Trump's remarks about an unproven link between Tylenol use during pregnancy and autism in children threaten to reignite a wave of litigation that the company had previously managed to quell. This comes after a federal court in December dismissed lawsuits alleging a connection between acetaminophen, Tylenol's active ingredient, and the developmental disorder.

Adding to Kenvue's woes, the US Food and Drug Administration (FDA) has initiated steps towards mandating a label change for products containing acetaminophen. This new label would state that the ingredient is associated with a higher risk of autism in children when taken by pregnant women. The FDA has also dispatched a corresponding letter to physicians nationwide. Legal experts suggest that if the FDA successfully compels Kenvue to incorporate autism risks onto Tylenol's label, consumers pursuing lawsuits against the company for their child's autism could potentially leverage these new warnings as crucial evidence in court.

This renewed legal battle poses a severe threat to Kenvue, a company already grappling with efforts to revitalize its business, reverse declining sales, and satisfy investors under interim CEO Kirk Perry. It marks the company's most substantial public relations challenge since the tragic incidents of cyanide-laced Tylenol capsules in the 1980s. Mark Lanier, a seasoned plaintiffs' lawyer who famously secured a $4.7 billion verdict in 2018 against Kenvue's former parent, Johnson & Johnson, for hiding cancer risks of baby powder, stated that the FDA's 'Dear Doctor' warning breathes new life into long-held suspicions and will bring the issue to the forefront once more. Stacey Lee, a law professor at Johns Hopkins University, emphasized that the new FDA-mandated warning could be powerful evidence for juries, even if it doesn't explicitly establish a causal relationship, as current research studies cannot definitively determine causality.

Despite these developments, Kenvue maintains its position, stating that the FDA's notice indicates 'a causal relationship has not been established.' A Kenvue spokesperson affirmed, “We stand with the science and believe we will continue to be successful in litigation as claims lack legal merit and scientific support.” This stance is echoed by the World Health Organization, which on Wednesday stated there is currently no conclusive scientific evidence linking autism and acetaminophen use during pregnancy, despite extensive research. While Kenvue might consider legal action against the federal government, legal experts deem its chances of success slim, given the wide latitude courts grant the FDA in assessing health risks, particularly those concerning pregnancy.

The mounting legal risks arrive during a tumultuous period for Kenvue. In the two years since its spin-off from Johnson & Johnson, the consumer products giant has struggled to establish stable footing under CEO Thibaut Mongon, attracting significant pressure from activist investors. Earlier this year, Kenvue appointed Jeffrey Smith, CEO of Starboard Value, to its board to avert a proxy battle. Other investment firms, like TOMS Capital Investment Management and Third Point, have also acquired stakes with aims to influence Kenvue's strategy, including pushing for portfolio trimming. In response, Kenvue announced several changes this summer, including Perry's appointment as interim CEO and a strategic review of its brand portfolio, which encompasses Neutrogena and Band-Aid, and potentially selling smaller skincare brands.

The company is also planning to streamline brand management by reorganizing leadership teams to a regional model, effective January. The broader economic climate has further exacerbated Kenvue's difficulties, as consumers reduce spending due to persistent inflation, a decelerating labor market, and high interest rates. Kenvue has reported organic sales contractions for two consecutive quarters, a trend analysts predict will continue. The company recently lowered its full-year sales target due to execution issues expected to persist. Tylenol, contributing a mid-to-high single-digit percentage of sales, is Kenvue’s largest brand, according to Morningstar analyst Keonhee Kim.

Citi analyst Filippo Falorni warns that the government’s warnings against Tylenol could not only expose Kenvue to extensive legal liabilities but also significantly damage the brand and decrease consumption, potentially affecting a broader consumer base beyond expecting mothers. Conversely, the wider scientific community has voiced concerns that the government’s claims could lead to public confusion regarding the treatment of fevers, a condition particularly dangerous for pregnant mothers and their children.